Ichor Medical Systems

Executive Summary

Ichor Medical Systems is a San Diego-based biotechnology company specializing in the TriGrid Delivery System, an advanced electroporation platform that enhances the delivery of nucleic acid therapeutics and vaccines. Founded in 1995, Ichor operates as a technology provider, licensing its platform to pharmaceutical and biotechnology partners for the development of DNA-based drugs. The TriGrid system is designed to improve cellular uptake of DNA vaccines and gene therapies, potentially increasing their efficacy and enabling new treatment modalities. By focusing on strategic partnerships rather than developing its own pipeline, Ichor reduces development risk while capitalizing on the growing demand for non-viral delivery technologies. The company's platform has been deployed in multiple preclinical and clinical programs, positioning it as a key enabler in the nucleic acid therapeutics space. With the increasing interest in DNA vaccines and gene therapies, Ichor is well-positioned to benefit from the expansion of its partners' pipelines and new licensing agreements.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new partnership or licensing deal70% success
• Q4 2026Clinical data readout from a partner using TriGrid in DNA vaccine trial50% success
• 2026Next-generation TriGrid platform update or patent milestone60% success